ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

9.400 +0.020 (+0.21%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ProMIS Neurosciences Inc. - Common Shares

< Previous 1 2 3 4 5 Next >

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

April 09, 2024

Study results support ProMIS’ TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS)

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

April 04, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023 ↗

April 01, 2024

PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

April 01, 2024

Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

March 11, 2024

Adds Key U.S. and International Patent Allowances to Further Protect the Company’s Monoclonal Antibody Therapeutic for the Treatment of Alzheimer’s Disease

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

February 22, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

January 22, 2024

Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson’s disease and Dementia with Lewy bodies

From ProMIS Neurosciences Inc.

Via GlobeNewswire

Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

January 19, 2024

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode...

Via Benzinga

ProMIS Neurosciences Issues Letter to Shareholders

January 08, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences, Inc. Announces Leadership Transition

January 03, 2024

Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Announces Publication on Novel Target for ALS

December 20, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease

November 20, 2023

Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human study

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

November 14, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

September 08, 2023

At-the-Market fundraise to support Company through several potentially value-creating milestones and beyond

From ProMIS Neurosciences Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 3, 2023 ↗

October 03, 2023

Via Benzinga

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 06, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

Crude Oil Falls; Dick's Sporting Goods Earnings Miss Views ↗

August 22, 2023

U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling over 100 points on Tuesday. The Dow traded down 0.39% to 34,330.87 while the NASDAQ rose 0.24% to 13,530.50. The...

Via Benzinga

Topics Earnings Stocks

Why ProMIS Neurosciences Shares Are Trading Higher By 33%; Here Are 20 Stocks Moving Premarket ↗

August 22, 2023

Gainers Axcella Health Inc. (NASDAQ: AXLA) shares gained 65% to $0.2887 in pre-market trading after gaining 12% on Monday. The company recently posted a narrower-than-expected quarterly loss.

Via Benzinga

Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

August 22, 2023

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares jumped 42.8% to $5.60 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

August 22, 2023

We're starting off Tuesday with a breakdown of the biggest pre-market stock movers investors will want to keep an eye on!

Via InvestorPlace

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

August 21, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

August 14, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket ↗

July 18, 2023

Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

July 18, 2023

It's time to start off trading for Tuesday with a breakdown of the biggest pre-market stock movers worth watching this morning.

Via InvestorPlace

Crude Oil Falls; GreenPower Motor Company Shares Spike Higher ↗

July 17, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 0.25% on Monday. The Dow traded up 0.25% to 34,596.04 while the NASDAQ rose 0.92% to 14,243.64. The S&P 500, also rose,...

Via Benzinga

Why ProMIS Neurosciences Stock Surged Today ↗

July 17, 2023

ProMIS Neurosciences Inc. (NASDAQ: PMN) shares skyrocketed Monday after the company presented preclinical data supporting the potential therapeutic advantage of its lead candidate for Alzheimer's...

Via Benzinga

Nasdaq Gains 100 Points; Guaranty Bancshares Posts Upbeat Results ↗

July 17, 2023

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Monday. The Dow traded up 0.19% to 34,574.01 while the NASDAQ rose 0.71% to 14,214.50. The S&P...

Via Benzinga

Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 17, 2023

Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived...

Via Benzinga

ProMIS Neurosciences (NASDAQ: PMN) Unveils Potential Therapeutic Advantage of PMN310 in Alzheimer’s Disease

July 17, 2023

Rationally Designed PMN310 Targets Toxic Amyloid-Beta Oligomers Selectively and Efficiently ProMIS Neurosciences, a pioneering biotech firm specializing in antibody therapeutics

Via Spotlight Growth

US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July ↗

July 17, 2023

U.S. stocks traded slightly higher this morning, with the Dow Jones moving higher by around 20 points on Monday. Following the market opening Monday, the Dow traded up 0.06% to 34,529.57 while the...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.